Who is sponsoring NCT03421574?

NCT03421574 is sponsored by Sunnybrook Health Sciences Centre.

What drugs are being tested in NCT03421574?

Interventions in NCT03421574: MR-guided Focused Ultrasound.

What condition does NCT03421574 study?

NCT03421574 studies Major Depressive Disorder.

Is NCT03421574 still recruiting?

NCT03421574 is currently completed. Last updated 5 December 2023.

Last reviewed 2023-12-05 · How we verify

NCT03421574

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression

Completed NA Last updated 5 December 2023

What this trial tests

NA trial testing MR-guided Focused Ultrasound in Major Depressive Disorder in 18 participants. Completed in 28 July 2021.

Timeline

19 January 2018

Primary endpoint
28 July 2021

28 July 2021

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	19 January 2018
Primary completion	28 July 2021
Estimated completion	28 July 2021
Sites	1 location across Canada

Drugs / interventions tested

MR-guided Focused Ultrasound

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

Adults 20 to 80, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study is to evaluate the safety and initial efficacy of MRgFUS for patients with treatment-refractory Major Depression. This study is designed as a prospective, single arm, nonrandomized study. Assessments will be made before and after MRgFUS for adverse events related to treatment, for clinical symptom relief, and quality of life (QoL). The target in the brain chosen for ablation will be the anterior limb of the internal capsule (i.e 'capsulotomy').

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Magnetic Resonance-Guided Focused Ultrasound : Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening.
Lee EJ, Fomenko A, Lozano AM. · · 2019 · cited 45× · PMID 30630292 · DOI 10.3340/jkns.2018.0180
Magnetic Resonance-Guided Focused Ultrasound in Neurosurgery: Taking Lessons from the Past to Inform the Future.
Jung NY, Chang JW. · · 2018 · cited 24× · PMID 30369860 · DOI 10.3346/jkms.2018.33.e279
Examining cognitive change in magnetic resonance-guided focused ultrasound capsulotomy for psychiatric illness.
Davidson B, Hamani C, Meng Y, Baskaran A, et al · · 2020 · cited 18× · PMID 33177508 · DOI 10.1038/s41398-020-01072-1
Targeted manipulation of pain neural networks: The potential of focused ultrasound for treatment of chronic pain.
Todd N, McDannold N, Borsook D. · · 2020 · cited 13× · PMID 32534900 · DOI 10.1016/j.neubiorev.2020.06.007
Commonly used outcome measures in neurosurgical trials for major depressive disorder might not capture clinically meaningful treatment effects.
Rabin JS, Nyman AJ, Davidson B, Zakzanis KK, et al · · 2022 · cited 4× · PMID 35078915 · DOI 10.1136/jnnp-2021-327688
Ultrasound Applications in the Treatment of Major Depressive Disorder: A Systematic Review of Techniques and Therapeutic Potentials in Clinical Trials and Animal Model Studies.
Tan G, Chen H, Leuthardt EC. · · 2026 · cited 1× · PMID 41105071 · DOI 10.1016/j.neurom.2025.08.001

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03421574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
Last refreshed: 5 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03421574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing